GILDGilead Sciences, Inc.

Filed with the SEC on October 29, 2026 | Form 8-K (Items 2.02, 9.01) Current Price: $175.32 | Today's Change: +5.87%

---

What Happened

Gilead Sciences filed an 8-K with the SEC on October 29, 2026, reporting its third-quarter FY2026 financial results under Item 2.02 (Results of Operations and Financial Condition). Revenue from contracts with customers (excluding assessed tax) reached $21.52 billion for the quarter, while the company reported net income of $6.33 billion — a figure that underscores the breadth of Gilead's current earnings power. Operating income for the period came in at $8.04 billion, and the company delivered diluted earnings per share of $5.04, with basic EPS at $5.08.

---

Why It Matters

The scale of these results is striking. A single-quarter net income of $6.33 billion and operating income of $8.04 billion reflect a business generating substantial cash at the operating level. For investors, the key near-term implications are:

• Revenue run-rate: With $21.52 billion in quarterly revenue, Gilead is operating at an annualized revenue pace well above $85 billion — a dramatic expansion from the $22.13 billion in full-year FY2020 revenues also noted in the filing's XBRL data, illustrating how materially the company's scale has changed over the intervening years.
• Margin story: Operating income of $8.04 billion on revenues of $21.52 billion implies an operating margin of approximately 37% — a level that signals disciplined cost management alongside top-line growth.
• EPS delivery: Diluted EPS of $5.04 in a single quarter gives investors a tangible sense of per-share earnings momentum heading into the final quarter of the fiscal year.
• Market reaction: The stock's near +5.87% move on the day of the report reflects market participants repricing the earnings power upward, consistent with a meaningful positive surprise.

---

Analysis

Gilead's Q3 FY2026 results point to a company that has undergone a fundamental transformation from its earlier profile. The contrast between the $22.13 billion in full-year FY2020 revenue and a single quarter of $21.52 billion in FY2026 is the most striking single data point in this filing — it tells a story of portfolio expansion, whether through organic product growth, acquisitions, or both, that has reshaped Gilead's financial footprint over roughly six years.

The operating income figure of $8.04 billion is particularly worth watching. An operating margin near 37% at this revenue scale is not trivial to sustain and will be a key metric for analysts as they assess whether these results are repeatable in Q4 and into FY2027. Investors should pay close attention to any management commentary on the composition of revenue — which product lines are driving the top line, and whether any are subject to near-term pricing pressure, patent exposure, or competitive dynamics.

The near-6% stock price jump on the day suggests that either the headline numbers exceeded consensus expectations or that guidance commentary (if released alongside this filing) was constructive. Given this report is grounded solely in the structured XBRL filing data, the specific drivers behind the beat — product mix, pricing, volume — are not available here and should be sought in the full earnings release and management commentary.

What to watch next:

• Q4 FY2026 guidance and whether management reaffirms or upgrades the full-year outlook
• Product-level revenue breakdown to understand which franchises are driving the exceptional quarterly performance
• Capital allocation signals — at this level of earnings generation, buyback and dividend policy will be closely scrutinized

---

Disclaimer

This report is a news and informational analysis based solely on data extracted from Gilead Sciences' SEC filing dated October 29, 2026, and publicly available market data. It does not constitute investment advice, a solicitation to buy or sell securities, or an equity research rating. No price target or Buy/Hold/Sell recommendation is expressed or implied. Readers should conduct their own due diligence and consult a qualified financial adviser before making any investment decision.

Source

Filed with the SEC on 2026-10-29. Read the original filing on EDGAR: https://www.sec.gov/Archives/edgar/data/882095/000088209526000037/gild-20261029.htm